NCT02159755View on ClinicalTrials.gov

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 13, 2014

Primary Completion Date

June 25, 2018

Study Completion Date

June 6, 2026

Conditions
Recurrent Mantle Cell Lymphoma
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Palbociclib

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (4)

10065

NYP/Weill Cornell Medical Center, New York

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

43210

Ohio State University Comprehensive Cancer Center, Columbus

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02159755 - Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter